The estimated Net Worth of Lauren P Silvernail is at least $4.9 Milione dollars as of 17 May 2022. Mrs. Silvernail owns over 68,204 units of Evolus Inc stock worth over $2,161,789 and over the last 11 years she sold EOLS stock worth over $1,712,833. In addition, she makes $1,021,330 as Chief Financial Officer e Executive Vice President - Corporate Development at Evolus Inc.
Lauren has made over 15 trades of the Evolus Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 68,204 units of EOLS stock worth $871,647 on 17 May 2022.
The largest trade she's ever made was selling 68,204 units of Evolus Inc stock on 17 May 2022 worth over $871,647. On average, Lauren trades about 4,769 units every 60 days since 2014. As of 17 May 2022 she still owns at least 141,571 units of Evolus Inc stock.
You can see the complete history of Mrs. Silvernail stock trades at the bottom of the page.
Lauren P. Silvernail serves as Chief Financial Officer, Executive Vice President - Corporate Development of the Company. She has served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc. ("Revance"), a pharmaceutical research and development company, from December 2015 to May 2018 and as Revance's Chief Financial Officer and Executive Vice President, Corporate Development from March 2013 to December 2015. From 2003 to 2012, Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a pharmaceutical research and development company. From 1995 to 2003, Mrs. Silvernail served in various operating and corporate development positions with Allergan, Inc., a pharmaceutical company, including Vice President, Business Development. Prior to joining Allergan, Inc., Mrs. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and the audit committee of Nicox S.A. Mrs. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
As the Chief Financial Officer e Executive Vice President - Corporate Development of Evolus Inc, the total compensation of Lauren Silvernail at Evolus Inc is $1,021,330. There are 4 executives at Evolus Inc getting paid more, with Michael Jafar having the highest compensation of $3,929,160.
Lauren Silvernail is 61, she's been the Chief Financial Officer e Executive Vice President - Corporate Development of Evolus Inc since 2018. There are 3 older and 8 younger executives at Evolus Inc. The oldest executive at Evolus Inc is Peter Farrell, 78, who is the Independent Director.
Lauren's mailing address filed with the SEC is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205.
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox e 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Evolus Inc executives and other stock owners filed with the SEC include: